These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

903 related articles for article (PubMed ID: 18088159)

  • 21. [Methods for estimating personal costs of disease using retinal diseases as an example].
    Porz G; Scholl HP; Holz FG; Finger RP
    Ophthalmologe; 2010 Mar; 107(3):216-20, 222. PubMed ID: 20195614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
    Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
    J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe.
    Angelis A; Kanavos P; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Brodszky V; von der Schulenburg JM; Chevreul K; Persson U; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1(Suppl 1):31-42. PubMed ID: 27107597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe.
    Cavazza M; Kodra Y; Armeni P; De Santis M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Péntek M; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():19-29. PubMed ID: 27038625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Access to healthcare services for elderly patients with neovascular age-related macular degeneration].
    Finger RP; Holz FG
    Ophthalmologe; 2012 May; 109(5):474-8. PubMed ID: 22581049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The burden of age-related macular degeneration: results of a cohort study in two French referral centres.
    Bonastre J; Le Pen C; Soubrane G; Quentel G
    Pharmacoeconomics; 2003; 21(3):181-90. PubMed ID: 12558468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incremental economic burden associated with exudative age-related macular degeneration: a population-based study.
    Kim S; Park SJ; Byun SJ; Park KH; Suh HS
    BMC Health Serv Res; 2019 Nov; 19(1):828. PubMed ID: 31718629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study.
    Fattore G; Torbica A; Susi A; Giovanni A; Benelli G; Gozzo M; Toso V
    BMC Neurol; 2012 Nov; 12():137. PubMed ID: 23150894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe.
    Péntek M; Gulácsi L; Brodszky V; Baji P; Boncz I; Pogány G; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Iskrov G; Schieppati A; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():89-98. PubMed ID: 27062257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The burden of age-related macular degeneration.
    Schmier JK; Jones ML; Halpern MT
    Pharmacoeconomics; 2006; 24(4):319-34. PubMed ID: 16605279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Age-related macular degeneration: a socioeconomic time bomb in our aging society].
    Schrader WF
    Ophthalmologe; 2006 Sep; 103(9):742-8. PubMed ID: 16924447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC; Brown MM; Rapuano S; Boyer D
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic Value of Anti-Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States.
    Mulligan K; Seabury SA; Dugel PU; Blim JF; Goldman DP; Humayun MS
    JAMA Ophthalmol; 2020 Jan; 138(1):40-47. PubMed ID: 31725830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relative cost of a line of vision in age-related macular degeneration.
    Smiddy WE
    Ophthalmology; 2007 May; 114(5):847-54. PubMed ID: 17306878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost of disorders of the brain in Europe 2010.
    Gustavsson A; Svensson M; Jacobi F; Allgulander C; Alonso J; Beghi E; Dodel R; Ekman M; Faravelli C; Fratiglioni L; Gannon B; Jones DH; Jennum P; Jordanova A; Jönsson L; Karampampa K; Knapp M; Kobelt G; Kurth T; Lieb R; Linde M; Ljungcrantz C; Maercker A; Melin B; Moscarelli M; Musayev A; Norwood F; Preisig M; Pugliatti M; Rehm J; Salvador-Carulla L; Schlehofer B; Simon R; Steinhausen HC; Stovner LJ; Vallat JM; Van den Bergh P; van Os J; Vos P; Xu W; Wittchen HU; Jönsson B; Olesen J;
    Eur Neuropsychopharmacol; 2011 Oct; 21(10):718-79. PubMed ID: 21924589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry.
    Lopez-Bastida J; Aranda-Reneo I; Rodríguez-Sánchez B; Peña-Longobardo LM; Ye X; Laeis P; Fronk EM; Palmerini E; Leithner A; Van de Sande MAJ
    Orphanet J Rare Dis; 2021 Jul; 16(1):294. PubMed ID: 34215312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe.
    Kuhlmann A; Schmidt T; Treskova M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Kanavos P; Taruscio D; Schieppati A; Iskrov G; Péntek M; Delgado C; von der Schulenburg JM; Persson U; Chevreul K; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():79-87. PubMed ID: 27086322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review.
    Schultz NM; Bhardwaj S; Barclay C; Gaspar L; Schwartz J
    Clin Ther; 2021 Oct; 43(10):1792-1818. PubMed ID: 34548176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC; Lade RJ; Adewoyin T; Chong NV
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations.
    Grieve R; Guerriero C; Walker J; Tomlin K; Langham J; Harding S; Chakravathy U; Carpenter J; Reeves BC;
    Ophthalmology; 2009 Dec; 116(12):2471-77.e1-2. PubMed ID: 19948278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.